News:

Dohmen releases new white paper on improved outsourcing model for orphan drug m...

The $114 billion orphan drug industry is traditionally served by a multi-channel model of disparate service providers. Each claims expertise in a specific niche of services, yet therapy adherence for rare disease patients is just over 58 percent. The Dohmen Life Science Services white paper e...

White Paper Image

What's new